Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis

Company Overview

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Key Stats

• Today's Range: $14.00 to $14.99
• 50-Day Range: $10.18 to $17.89
• 52-Week Range: $5.40 to $32.55
• Volume: 34,330 shs
• Average Volume: 30,328 shs
• Market Capitalization: $23.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

Cadrenal Therapeutics Stock Analysis - MarketRank™

Cadrenal Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 772nd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cadrenal Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($7.92) to ($3.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cadrenal Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cadrenal Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cadrenal Therapeutics has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.06% of the float of Cadrenal Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cadrenal Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cadrenal Therapeutics has recently increased by 65.27%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cadrenal Therapeutics does not currently pay a dividend.

Dividend Growth

Cadrenal Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.06% of the float of Cadrenal Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cadrenal Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cadrenal Therapeutics has recently increased by 65.27%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.41

News Sentiment

Cadrenal Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cadrenal Therapeutics this week, compared to 1 article on an average week.

Search Interest

7 people have searched for CVKD on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

MarketBeat Follows

2 people have added Cadrenal Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

48.62% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.92% of the stock of Cadrenal Therapeutics is held by institutions.

CVKD Stock Analysis - Frequently Asked Questions

How have CVKD shares performed this year?

Cadrenal Therapeutics' stock was trading at $7.1850 on January 1st, 2024. Since then, CVKD stock has increased by 102.2% and is now trading at $14.53.
View the best growth stocks for 2024 here.

When did Cadrenal Therapeutics IPO?

Cadrenal Therapeutics (CVKD) raised $7 million in an IPO on Friday, January 20th 2023. The company issued 1,400,000 shares at a price of $5.00 per share.

How do I buy shares of Cadrenal Therapeutics?

Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cadrenal Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cadrenal Therapeutics investors own include Clean Energy Fuels (CLNE), Paycom Software (PAYC), uniQure (QURE), AbCellera Biologics (ABCL), Grayscale Ethereum Trust (ETH) (ETHE), Mitsubishi UFJ Financial Group (MUFG) and Oatly Group (OTLY).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/10/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CVKD
• CUSIP: N/A
• CIK: 1937993
• Web: www.cadrenal.com
• Phone: 904-300-0701
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $18.00
• High Stock Price Target: $32.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +23.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.6789)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,360,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -142.95%
• Return on Assets: -118.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.69
• Quick Ratio: 3.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.06 per share
• Price / Book: 7.05

Miscellaneous

• Outstanding Shares: 1,660,000
• Free Float: 852,000
• Market Cap: $24.12 million
• Optionable: Not Optionable
• Beta: 1.52